dc.creator | Schattenberg, Jorn M. | es |
dc.creator | Lazarus, Jeffrey V. | es |
dc.creator | Newsome, Philip N. | es |
dc.creator | Serfaty, Lawrence | es |
dc.creator | Aghemo, Alessio | es |
dc.creator | Augustin, Salvador | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | Ratziu, Vlad | es |
dc.date.accessioned | 2022-10-07T15:11:17Z | |
dc.date.available | 2022-10-07T15:11:17Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Schattenberg, J.M., Lazarus, J.V., Newsome, P.N., Serfaty, L., Aghemo, A., Augustin, S.,...,Ratziu, V. (2021). Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver International, 41 (6), 1227-1242. https://doi.org/10.1111/liv.14825. | |
dc.identifier.issn | 1478-3223 | es |
dc.identifier.uri | https://hdl.handle.net/11441/137733 | |
dc.description.abstract | Background and aims: Non-alcoholic
steatohepatitis (NASH) is a chronic disease
that can progress to end-stage
liver disease (ESLD). A large proportion of early-stage
NASH patients remain undiagnosed compared to those with advanced fibrosis, who
are more likely to receive disease management interventions. This study estimated
the disease burden and economic impact of diagnosed NASH in the adult population
of France, Germany, Italy, Spain and the United Kingdom in 2018.
Methods: The socioeconomic burden of diagnosed NASH was estimated using cost-of-
illness
methodology applying a prevalence approach to estimate the number of
adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed
patients do not incur costs in the study, the probability of diagnosis is central
to cost estimation. The analysis was based on a literature review, databases and consultation
with clinical experts, economists and patient groups.
Results: The proportion of adult NASH patients with a diagnosis ranged from 11.9% to
12.7% across countries, which increased to 38.8%-39.1%
for advanced fibrosis (F3-F4
compensated cirrhosis). Total economic costs were €8548-19
546M. Of these, health
system costs were €619-1292M.
Total wellbeing costs were €41 536-90
379M. The
majority of the undiagnosed population (87.3%-88.2%
of total prevalence) was found
to have early-stage
NASH, which, left untreated, may progress to more resource consuming
ESLD over time.
Conclusions: This study found that the majority of economic and wellbeing costs of
NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients
could reduce future healthcare costs. | es |
dc.format | application/pdf | es |
dc.format.extent | 16 p. | es |
dc.language.iso | eng | es |
dc.publisher | Wiley-Blackwell | es |
dc.relation.ispartof | Liver International, 41 (6), 1227-1242. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Burden of disease | es |
dc.subject | Cost-of- illness analysis | es |
dc.subject | Economic impact | es |
dc.subject | Healthcare resource utilisation | es |
dc.subject | Non-alcoholic steatohepatitis (NASH) | es |
dc.title | Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14825 | es |
dc.identifier.doi | 10.1111/liv.14825 | es |
dc.journaltitle | Liver International | es |
dc.publication.volumen | 41 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | 1227 | es |
dc.publication.endPage | 1242 | es |